Share on StockTwits

Shares of Foundation Medicine (NYSE:FMI) have received a consensus recommendation of “Hold” from the eight analysts that are currently covering the company, reports. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $38.80.

A number of research firms have recently commented on FMI. Analysts at Janney Montgomery Scott initiated coverage on shares of Foundation Medicine in a research note on Wednesday. They set a “neutral” rating and a $28.00 price target on the stock. Separately, analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th. Finally, analysts at William Blair initiated coverage on shares of Foundation Medicine in a research note on Thursday, April 17th. They set a “market perform” rating on the stock.

In other Foundation Medicine news, COO Steven J. Kafka sold 5,000 shares of Foundation Medicine stock on the open market in a transaction that occurred on Thursday, June 19th. The stock was sold at an average price of $24.46, for a total value of $122,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Foundation Medicine (NYSE:FMI) traded up 3.30% during mid-day trading on Thursday, hitting $25.36. The stock had a trading volume of 166,082 shares. Foundation Medicine has a 1-year low of $19.513 and a 1-year high of $45.00. The stock has a 50-day moving average of $23.10 and a 200-day moving average of $28.33. The company’s market cap is $714.9 million.

Foundation Medicine (NYSE:FMI) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.48) by $0.04. The company had revenue of $11.45 million for the quarter, compared to the consensus estimate of $11.33 million. The company’s quarterly revenue was up 120.2% on a year-over-year basis. On average, analysts predict that Foundation Medicine will post $-1.81 earnings per share for the current fiscal year.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.